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ABSTRACT
Hepcidin regulates serum iron levels and its dosage is used in differential diagnostic of iron-related
pathologies. We use the data collected in the HEPMEN study to investigate the joint dynamics of
serum hepcidin and iron during the menstrual cycle in healthy women.
Ninety  menstruating women were  recruited  after  a  screening  visit.  Six  fasting blood samples  for
determination of iron-status variables were taken in the morning throughout the cycle, starting on the
second day of the period. Non-linear mixed effect models were used to describe the evolution of iron
and hepcidin. Demographic and medical covariates were tested for their effect on model parameters.
Parameter  estimation  was  performed  using  the  SAEM  algorithm  implemented  in  the  Monolix
software.
A general pattern was observed for both hepcidin and iron, consisting of an initial decrease during
menstruation, followed by a rebound and stabilising during the second half of the cycle. We developed
a joint model including a menstruation-induced decrease of both molecules at the beginning of the
menses, and a rebound effect after menses. Iron stimulated the release of hepcidin. Several covariates,
including contraception, amount of blood loss and ferritin, were found to influence the parameters.
The joint model of iron and hepcidin was able to describe the fluctuations induced by blood loss from
menstruation in healthy non-menopausal women and the subsequent regulation. The HEPMEN study
showed fluctuations of iron-status variables during the menstrual cycle, which should be considered
when using hepcidin measurements for diagnostic purposes in women of child-bearing potential.
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INTRODUCTION
Iron is a very important element in mammals, and it is the most abundant trace element in
humans with a total body amount of 2.5-4.5 g (1). It participates in cellular respiration, in DNA repair
and synthesis and in oxygen transfer (2). It is naturally present in the body, with  most of the body iron
(60%) used within the red blood cell haemoglobin to bind oxygen. There is no regulated pathway to
excrete iron from the body, and as a result body iron levels are mainly regulated by daily absorption of
iron from food, via modulation of the rate of iron entry through the duodenal mucosa, which affects
net iron absorption. Serum iron levels are maintained stable by a complex regulation network, affected
by the rate of iron recycling from macrophages and transfer from other tissue stores. Figure 1 shows a
simplified schematic of iron circulation in the body: ferric iron (iron(III)) absorbed from food is first
reduced to ferrous iron (iron(II)) and absorbed by enterocytes through binding with the divalent metal
transporter  1 (DMTP1),  As free ferrous iron catalyses the formation of free radical  from reactive
oxygen species,  protective mechanisms have evolved to protect  the cells  from its  toxicity. Iron is
stored  in  hepatocytes,  enterocytes  and  macrophages  as  ferritin,  a  complex  formed  by  apoferritin
binding iron in the ferric state. Export of iron from duodenal enterocytes and macrophages into plasma
is mediated by the iron transporter ferroportin. Hepcidin, a hormone peptide mainly synthesised by the
hepatocytes (6-7), binds to ferroportin resulting in its internalisation and degradation (8-10), thereby
blocking iron export. Ferric iron resulting from oxydation of iron released by ferroportin is taken up
by transferrin which transports it mainly to the liver for storage and the blood marrow for production
of red blood cells. 
Once iron has entered the body it is surprisingly difficult to remove it by other means than
bleeding,  either natural  or  accidental,  as only a very small amount of iron passes into urine or is
excreted in the intestine (3). Natural bleeding occurs in women during their period every month, where
they generally lose 10 to 40 mg of iron. This triggers the regulation network, and leads to fluctuations
in  iron  levels  throughout  the  menstrual  cycle,  as  evidenced in  an  epidemiological  study in  1712
women aged 18 to 44 years, with regular menstrual periods, which reported significant variation of
iron  status  during  the  menstrual  cycle  (4).  Menstruating  women  also  tend  to  have  lower  serum
hepcidin than men of similar age, as reflected in the normal laboratory ranges (5). The most prevalent
iron  disorder  is  anemia  (too  little  iron),  but  there  is  also  a  range  of  iron  overload  disorders
(hemochromatosis), with both genetic (thalassemia) and non-genetic causes, which lead to long-term
organ  toxicity.   The  differential  diagnostic  of  these  pathologies  involves  dosing  serum  iron,
haemoglobin, and ferritin, as well as the two key players of the iron regulation network, ferroportin
and hepcidin. 
Hepcidin production decreases in response to low concentrations of circulating iron, in order
to restore normal levels,  and when erythropoiesis is activated,  to release iron for the synthesis of
erythrocytes (11). This stimulates both the release of stored iron and the absorption of dietary iron.
Conversely, hepcidin concentrations increase when iron stores are high (12-13) and in the presence of
inflammation (14-15), which decreases intestinal absorption and iron release from storage. Reduced
hepcidin levels can be observed as the result of hypoxia, while inflammation or infection can stimulate
hepcidin production. Measuring hepcidin along with serum iron can be useful in differential diagnostic
of iron-related disorders, particularly chronic anaemia. Indeed low levels of serum iron are associated
with high serum hepcidin in anaemia from chronic inflammatory disease but with low serum hepcidin
in iron-deficiency anemia (de Kroot et al. 2011).  There is no specific indication for dosing hepcidin
during menses  per se but when non-menopausal women are affected by anaemia timing for dosing
hepcidin during cycle should be taken into account to interpret the results.. Because hepcidin and iron
concentrations are so intimately linked, we can expect hepcidin levels to also respond to iron loss
through bleeding.
We therefore  designed  the  HEPMEN (named  after  HEPcidin  during  MENses)  study  to
investigate  the  evolution  of  iron-status  variables  in  healthy  menstruating  women  during  their
menstrual cycle and help decide when to measure hepcidin for diagnostic purposes. In this paper, we
develop the first joint model for iron and hepcidin concentrations during the menstrual cycle. 
3
METHODS
Experimental Design
The  HEPMEN study  was  a  multicenter  observational  study  performed  in  4  university
hospitals in France (Brest, Nantes, Rennes, Tours). It included 90 healthy women aged 19 to 44 years
with  regular  menstrual  cycles  and  menses  length  between  3  and  5  days.  No  treatments  were
administered  during  the  study.  Sixty-one  percent  of  the  women  took  daily  oral  contraceptives.
Demographic variables were recorded during an inclusion visit, including age, height, weight, body
mass index, waist circumference and Higham’s score, which evaluates the abundance of menstrual
periods (16).  Higham's score was obtained as the mean of the three last  scores calculated by the
patients. 
Sampling Design
Fasting blood samples (4mL) were collected from each woman on six occasions distributed
during  the  menstrual  cycle  in  order  to  measure  concentrations  of  serum  hepcidin,  serum  iron,
transferrin saturation, serum transferrin, serum ferritin and haemoglobin. The visits were planned at
the same time each day, between 8 am and 9 am. The sampling protocol was optimised using the
PFIM software (17-18) to maximise the information collected in the study in view of a joint modelling
of iron and hepcidin. For the optimisation, we used the pharmacokinetic model of hepcidin developed
by  Xiao  et  al.  (19)  and  reflecting  the  changes  in  hepcidin  concentrations  in  monkeys  after  an
administration of an antibody, where hepcidin was modelled through a turnover model. We used the
same model for iron, as a simplification of the iron regulatory system. We used the typical 1 mg daily
iron loss reported in medical literature and a baseline iron value of 1 mg/L to compute the input and
output parameters to the iron model. Iron loss during menses was estimated to be 0.05 d -1 based on
typical blood loss and iron concentrations. For hepcidin, we used the elimination rate reported in (19),
as well as a baseline value of 10 nmol/L for hepcidin, the average value from data available in house
as part of routine measurements performed in healthy volunteers taking part in clinical trials. Finally,
we assumed two linear models to account for the effect  of  iron on hepcidin and vice-versa,  with
parameters respectively equal to 0.5 and 0.2 which gave a plausible magnitude of variation during the
cycle  compared  to  iron  changes  in  menstruating  women  reported  in  (4),  and  assuming  similar
variations for hepcidin. A sigmoid model was not identifiable because of the very rapid turnover of
hepcidin.  We  assumed  an  interindividual  variability  of  30%  for  most  parameters,  except  the
elimination  rate  of  hepcidin  and  the  effect  of  hepcidin  on  iron,  which  were  fixed  to  allow  the
optimisation algorithm to converge. We limited the number of samples to 6 per subject and used the
Fedorov-Wynn algorithm to optimise over a discrete set of sampling times (one per day of the cycle)
with the following constraints: 3 time-points between day 1 (beginning of menses) and day 6; 1 point
during the rebound after menses (between days 6 and 12); 1 point mid-cycle (between days 12 and 19)
and 1 point at the end of the cycle (between days 26 and 29). The first blood sample was collected on
the second day of menses and the optimal protocol was then adjusted based on the day of the week
that menses began, to avoid sampling during weekends. This also served to make the protocol more
robust as it allowed the samples to be spread out during the cycle.
Ethics statement
This study was reviewed by the ethical committee of Rennes and approved by the National
Security  Agency  of  the  Medicine  and the  products  of  health  (ANSM).  Signed,  written  informed
consent was obtained from all participants.
Bioanalytical methods 
The samples were collected in the four participating hospitals. Blood samples were collected
in fasting subjects, in the morning between 8 and 9 am. Samples for hepcidin determination were
collected on dry tubes, then centrifuged at 1500g during 20 minutes at 4°C.  Except for the sample
collected at the inclusion visit, which was treated on site, all serum samples were frozen at -80°C and
sent to the Laboratory of Rennes’s hospital for centralised analyses. Laboratory assays were performed
in the biochemistry laboratory at the Rennes University Hospital (Pontchaillou, Rennes, France).  The
assays of serum iron, transferrin and ferritin were performed on a cobas ® 8000 (Roche Diagnostics
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GmbH, Mannheim). Serum iron was quantified in a colorimetric manner using a ferrozine method
(Iron2 Iron Gen2 Roche-ref.  03183696122).  Serum transferrin  was measured by immunochemical
turbidimetry (Tina-quant Transferrin ver.2 ref. 05588855 190) and transferrin saturation was calculated
using the formula:   transferrin saturation (%) = (iron (µmol/l)/(transferrin  (g/l)  x 25)  × 100.  The
Ferritin level was determined with an electrochemiluminescence immunoassay (Ferritin ECLIA Roche
ref.  ms_04491785190). The laboratory’s within-run (intra-assay) precision and between-run (inter-
assay) precision were respectively 1.4% and 2.5% for iron, 2% and 2.5% for transferrin, 1.5 and 4.1%
for ferritin. The lower quantification limit was 0.9µmol/l, 0.1g/l and 0.5µg/l for iron, transferrin and
ferritin  respectively.  Serum  hepcidin-25  was  quantified  using  a  competition  CE-marked  Enzyme
Immunoassay  (EIA)  kit  (S-1337;  Bachem  Torrance  USA)  following  the  instructions  of  the
manufacturer. Serum samples were  diluted in supplied standard diluent and analyzed in duplicate at
450nm on a microplate reader (Victor®-Perkin Elmer Massachusetts USA). Hepcidin  concentrations
were interpolated from standard curves generated by logistic 4-parameter nonlinear curve fitting.  The
intra-assay and inter-assay coefficient of variation was 3.5% and 6.3%, respectively and the lower
quantification limit was 0.01nmol/l. 
Statistical Model
The data consisted of repeated measurements in a population of women. Non-linear mixed
effect models were used for the analysis as they are well suited to longitudinal data. The observation y ij
measured at time tij for a subject i was modelled using the following equation:
(1)
where ni denotes the number of observations in subject i, j the index of the observation (j=1,…,n i), f
the structural model, θi the individual parameters for subject i, ε ij the measurement error and zi the
individual covariates.
The  between-subject  variability  was  modelled  through  a  log-normal  distribution  for  the
parameters θi so that the kth component of θi was defined as:
(2)
where µk is a population fixed effect and bik is the corresponding individual random effect. Continuous
covariates such as body mass index (BMI) were entered in the model through an exponential model,
modifying equation (2) to:
θik = µk (BMIii/tBMI)BMI ebik 
where tBMI is a typical value of weight (either the median in the population or a set value) and BMI
the  estimated effect.  For a categorical  covariate  such as contraception,  the  reference value of  the
parameter for women taking contraception was assumed to follow equation (2) while for women not
taking contraception, (2) was modified to:
θik = µk econtraception ebik 
A combined error model was used to describe the variance of the residual error for both
serum iron and serum hepcidin:
var(ik) = (a+b f(i,tij,zij))2 (3)
where the variance parameters a (additive part) and b (proportional part) are respectively a iron and biron
for iron and aHep and bHep for hepcidin.
The  maximum  likelihood  estimates  of  the  parameters  were  obtained  using  the  SAEM
algorithm implemented in the Monolix software (4.3.2 version standalone Windows, 32 bits) (20). The
log-likelihood was computed using importance sampling (21).
Model Building
To build  the  joint  model,  we  first  explored  structural  models  separately  for  iron  and
hepcidin,  then  combined  the  two  models  testing  different  link  functions  to  describe  the  mutual
regulation. The separate fits also provided appropriate initial estimates for the parameters of the joint
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model. A diagonal covariance matrix was used at this stage to represent the interindividual variability,
and we tested whether there was significant covariance between certain parameters. During model
building, log-likelihood ratio tests (LRT) were used to compare nested models, including variability
structures; non-nested models were compared using the Bayesian information criterion (BIC).
In a second stage, we included covariates in the model through a stepwise procedure. The
covariate data included the demographic variables recorded at the inclusion visit, as well as reference
values of martial settings: serum transferrin, serum ferritin, haemoglobin and transferrin saturation.
The evolution of all the iron-status variables is shown in Figure 2. The plots show a similar evolution
for iron, hepcidin and saturation of serum transferrin, which all exhibit  a decrease during menses,
followed by a moderate rebound for  hepcidin and a marked rebound for the other  two variables.
Transferrin,  ferritin and hemoglobin do not  seem to consistently  vary during the cycle,  but  show
considerable interindividual variability. Transferrin saturation on the other hand was highly correlated
with iron (=0.92). Therefore only a reference value was included in the model as a covariate. In order
to  ensure  consistency  across  all  recruiting  centers,  the  reference  values  were  taken  as  the
concentrations obtained at the last appointment for each woman. We did not use the measurements
collected at the inclusion visit because these were obtained at different moment during the menstrual
cycle, in non-fasted conditions, and also because these samples were analysed in each participating
center while all other samples collected during the protocol were analysed centrally with the same
analytical method.  Inclusion of covariates was performed using a two stage stepwise approach, first
exploring the relationships for each parameter separately and then building the full covariate model. In
the first stage, for each parameter, a full covariate model including all potential relationships was built.
Covariates with a p-value for the Wald test larger than 0.2 were removed from the model in one step,
then  backward  selection  was  applied  to  remove  non-significant  covariates  one  at  a  time,  with  a
threshold of 0.05 for the Wald test, starting with the covariate which had the largest non-significant
covariate.  In  the  second  stage,  a  model  was  created  with  all  the  previous  covariate-parameter
relationship and backward selection was again applied using the same approach, until all covariates
remaining in the model were significant according to the Wald test.
Finally,  the  covariance  structure  was  refined,  by  testing  again  for  correlations  between
parameters  and by removing variances  when needed.  The final  model  was adjusted to obtain the
estimates of the parameters and their standard errors.
Three subjects were identified by the clinicians as having abnormal hepcidin concentrations.
Two of them had a very high serum hepcidin at one or two visits (4 to 7 times higher than all other
concentrations for that subject) and the concentrations were high at all visits for the third subject (2 to
3 times larger than the highest concentration of hepcidin in the data set).  A sensitivity analysis was
performed with the final model to evaluate their impact on parameter estimates.
Iron model
In the absence of perturbation, iron regulation maintains stable levels of serum iron in the
body. To reflect the endogenous levels of iron, we described the baseline evolution of iron through a
turnover model (23). In this model, the change in iron concentrations is the result of two compensating
mechanisms, constant endogenous secretion characterised by a parameter ksyn I, reflecting the release
of iron from storage,  and first-order elimination characterised by a parameter kout I,  reflecting the
uptake of iron and its disappearance from serum. The equation for this model, denoting Ir(t) serum
iron levels at time t, is:
dIr(t)/dt = ksynI– koutI Ir(t) (4)
In  menstruating  women,  blood loss  during  menses  results  in  iron  loss.  This  was  included in  the
turnover model as an increase in the elimination kout I, which was assumed to be koutI+kloss for a
duration of dloss days. We tested whether dloss could be estimated from the data or whether it should
be fixed to the duration of menses. Because Higham's score (HiS) reflects the quantity of blood lost
during menses, we tested the assumption that it influenced kloss through a loglinear function:
kloss= lossln(HiS)
In the standard turnover model concentrations of iron would return at their steady-state level
after the end of the perturbation, but here the data showed a marked overshoot of iron around mid-
cycle, reminiscent of the pattern observed when an organism adapts to change input conditions, a
situation known as tolerance (24). We tested several tolerance models including push-pull models (25)
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or effect-compartment models (26) which could reflect the regulation of iron namely through hepcidin.
Alternatively, an empirical model was built by assuming that iron release into serum increases by a
parameter krelI during a period of time starting mid-menses (tbeg) and lasting drel days. Because of
identifiability issues, tbeg was estimated using a grid approach between 1 and 5 days.
Hepcidin model
As hepcidin showed a similar evolution as iron, the models described above were also applied
to hepcidin. Because there were more fluctuations during the cycle than for iron, we tested for periodic
changes in the model parameters using sinusoidal functions for baseline ksynH or koutH:
koutH= koutH0+Rb*cos(2*acos(-1)*(t-decal)/lcycle))
where lcycle is the duration of the cycle, Rb the magnitude of variation and decal the day in the cycle
when koutH is equal to its average value.
Joint model
The two separate models for iron and hepcidin were then combined, and we investigated the
interaction between the two martial variables. We tested whether a mutual regulation could explain the
rebound observed at the end of menses, by adding a linear or sigmoid effect of one variable on the
synthesis of the other. For example, the effect of hepcidin on iron release into serum was modelled
through equations such as:
ksynI= H (He(t)-He(0))
or ksynI= H (He(t)-He(0))/(He(t)-He(0)+He50)
The final model is illustrated in Figure 3. Iron and hepcidin production were characterised by a
zero-order rate constant (ksynI and ksynH respectively) and their elimination were characterised by a
first-order rate constant (koutI and koutH respectively), and the production of hepcidin was influenced
by the  changes  in  iron  concentrations  through a  linear  model.  The  final  model  for  iron  (Ir)  and
hepcidin (He) was described by the following system of differential equations:
(4)
starting from initial conditions:
(5)
where t=0 is the beginning of the cycle, ksyn I, koutI, ksynH and koutH vary according to the schedule in
Figure  3 (right),  dloss  denotes  the  length of  menses  of  each subject  and was fixed to  individual
observed values, while drel denotes the length of the time period over which release is increased and
was estimated. In Figure 3, dcycle was fixed to the length of the cycle for each woman.
Model Evaluation
Model evaluation was based on visual inspection of diagnostic graphs (22): individual fits,
evaluating  the  predictive  capacity  of  the  model,  plots  of  the  predictions  versus  observations,
evaluating  the  quality  of  the  structural  model,  scatterplots  of  the  NPDE  (normalized  prediction
distribution errors) versus time and predicted concentrations, assessing the structural and statistical
models (27), and VPC (Visual Predictive Check) evaluating the ability of the model to reproduce the
observed data. NPDE and VPC were based on 1000 simulated datasets. These graphs were produced
for all the runs during the analysis and used in combination with the statistical criteria to guide model
building.
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To evaluate the stability of the final model, a run assessment was performed using Monolix:
10 runs were performed with a different seed for the random number generator, and different initial
parameters, randomly chosen within a range of ±20% centered on the estimates from the final model.
The 10 sets of estimates parameters were then compared to those obtained with the final run. We also
re-estimated the parameters for the final model excluding the three subjects identified by the clinicians
as having abnormal values of hepcidin to assess their influence on parameter estimates.
RESULTS
Evolution of iron-status variables during the study
Ninety  (90)  menstruating  women were included in  the  analysis.  Their  demographic  and
biological characteristics are shown in Table 1. The population was homogeneous, with small standard
deviations for the demographic covariates. Biological variability at the end of cycle visit ranged from
small (5.2%) for haemoglobin to large (83.4%) for ferritin, and was intermediate for serum transferrin
(17.0%) and transferrin saturation (34.9%).
Among the 90 patients, 67 had 6 blood samples, 20 had 5 and 3 subjects had 4. Overall, 514
measurements of iron and hepcidin were available. Since large variations were supposed to occur at
the beginning of the cycle, per protocol the bulk of the samples was collected during the first part of
the cycle, with fewer samples from day 14 onwards. 
Observed variations of serum iron and serum hepcidin throughout the menstrual cycle are
shown in Figure 2 as boxplots,  along with ther  other  iron-status variables.  Spaghetti  plots  of  the
individual profiles is provided in the Appendix (Figure S1) Considerable fluctuations were observed in
both iron and hepcidin levels with large variations in the shape of the individual profiles. A general
pattern was observed in the boxplots of Figure 2, consisting of an initial  decrease during menses,
followed by a rebound,  and a stabilization during the second half  of  the cycle.  The rebound was
marked, as both concentrations increased after the end of menses to reach higher values than baseline
concentrations. The boxplots in Figure 2 show a similar evolution for iron, hepcidin and saturation of
serum transferrin. The other iron-status variables (transferrin, ferritin and hemoglobin) do not seem to
consistently vary during the cycle, but show considerable interindividual variability.
Iron modelling
In a first step, iron and hepcidin were modelled separately to help guide the joint modelling
and provide appropriate initial estimates. Table S1 in Supplementary material shows the steps of the
model building for each variable.
The turnover  model  with blood loss  starting with menses  was first  adjusted to  the  data
(model I1).  The duration of blood loss could be fixed to the length of the menses (model I2).  As
expected, this model could not describe the rebound observed at mid-cycle in serum concentrations.
We then tested various tolerance models (models I3 and I4) but they failed to reproduce the extent of
the rebound. An empirical model assuming that iron release into serum increases by a parameter krel I
during a period of time starting during menses and lasting drel days performed better (models I6 and
I7), and a grid search showed mid-menses (day 2) performed well in terms of statistical criterion. An
alternative was to fix the beginning of the rebound at the end of menses (model 5).
We tested whether dloss could be estimated from the data, but better estimates were found
when dloss was fixed to the length of menses for every woman and when drel was estimated without
between-subject variability. Because kloss represents the rate of iron lost during menses, we tested
whether we could set kloss to be linearly related to Higham’s score, which evaluates the abundance of
menstrual periods, but this did not improve the results. The final model reflected the evolution of iron
adequately, as shown by the diagnostic graphs (Supplementary Figure S1), with a residual error around
30%.
Hepcidin modelling
The evolution of hepcidin during the menstrual cycle paralleled on average the evolution of
iron, as shown in Figure 1. We used the same baseline model as for iron, with parameters ksynH,and
koutH,  and  again  tested  various  assumptions  to  handle  the  mid-cycle  rebound  of  hepcidin
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concentrations. The residual error remained large for all model tested however, decreasing from 0.49
to 0.46 when the rebound was included.  A model  where koutH was assumed to have a sigmoidal
periodicity throughout the cycle was tested and improved the residual error to 0.4, however this model
was not kept in the following because it induced large fluctuations in the second part of the cycle
where we did not have sufficient data to confidently validate such behaviour, and also because for
some subjects  koutH became very small  and as  a result  hepcidin concentrations  did not  return to
baseline  at  the  end  of  the  cycle.  Diagnostic  graphs  for  the  final  hepcidin  model  are  shown  in
Supplementary Figure S2.
Iron and hepcidin modelling
The two separate models for iron and hepcidin were then combined, and we investigated the
interaction between the two martial variables. Table 2 shows key models tested in the joint analysis. In
the first model we combined the separate models for iron and hepcidin without a link between the two.
We then tested a model where hepcidin modifies the release of iron (ksynI, model 2), and this model
had a  similar  BIC,  while  a  model  where  iron  modifies  the  release  of  hepcidin  ksynH (model  3)
performed slightly better. A model including both link functions on the other hand had a worse BIC
(model  4),  so the  effect  of  hepcidin on iron was not  kept  in the model.  We then tested different
assumptions concerning the link between the two variables: we could assume the same (relative) loss
during menses (same kloss), and the same duration for the rebound. In model 6 the duration of the
rebound had a rather large estimation error (72%), but we could assume the interindividual variability
was negligible (model 7). We compared this joint model with a model where hepcidin concentration is
a  linear  function  of  iron  (He(t)= Ir(t));  although  the  BIC  decreased  by  a  little  over  4  points
(BIC=5715.7), the residual error for hepcidin increased back to 50% and we did not keep this model.
Because in some subjects the rebound for iron or hepcidin was not apparent, we also tested mixture
models  to  accommodate different  profiles  within  the  population,  but  these did not  provide  better
estimates (models 8 and 9). Finally, we also refined the residual error models. To avoid numerical
problems with a proportional error model we used a combined residual error model for the model
building. In the final model the additive part of the iron residual error was very small and poorly
estimated, and could be removed without changing the value of the log-likelihood or the estimated
parameters (model 9), or fixed to a small value (model 11, where aI was fixed to 0.001).
Therefore, in the final model (Figure 3), turnover models were used to describe both iron and
hepcidin evolution, and the changes in iron concentrations drive the production of hepcidin. The four
production and elimination parameters were modelled as time dependent, and their variations during
the cycle are depicted on the right hand side of Figure 3. The same parameter kloss increased the
elimination of both responses during menses, while the synthesis of iron and hepcidin increases by
krelI and krelH respectively for the same duration drel starting from day 2 of menses. Throughout the
menstrual cycle, serum iron affected the synthesis of hepcidin through a linear relationship involving a
parameter α.
The joint model provided a good fit for iron, with a residual error around 29%, while the
residual error was larger for hepcidin (48%), which was reflected in a large variability in the VPC
plots although the median profile appeared adequately predicted. The additive part of the error model
was estimated with a large estimation error; it was kept in the model to avoid numerical problems
during the estimation process but its estimated value was very small and does not influence the results.
Effect of covariates
The parameter estimates for the joint structural model are reported in the first column of
Table  4  (model  without  covariates).  There  was  substantial  interindividual  variability  for  several
parameters, so the next step in the analysis was to test whether covariates could explain part of the
variability.  Covariate model building was performed starting from model 7 in Table 2, assuming a
combined residual error model again to avoid running into numerical issues. For each parameter, we
first  built  a  full  model  with  all  potential  parameter-covariate  relationship;  in  a  second  step,  we
removed all the relationships for which the p-value of the Wald test for the covariate was higher than
0.2 (intermediate model); then the covariate model for the parameter was obtained by removing one by
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one all non-significant relationships (reduced model). Each of these steps is presented in models 2 to
28. Except for model 22 (selection on parameter krelH) all the reduced models had lower BIC than the
base model. No covariate was found to influence drel, while for koutI, the intermediate model was the
same as the final parameter model. The selected relationships were then combined in a full model
(model 29) and descending selection was again performed to obtain the final model (model 30). A
proportional error model was tested for the final model and found to yield similar parameter estimates
and log-likelihood values. The steps of the analysis are shown in Table 3.
After  stepwise model  building,  the following six covariates  were found to affect  one or
several parameters in the model: method of contraception, BMI, Height, Higham score, as well as the
end  of  cycle  values  of  haemoglobin  and  ferritin.  After  covariate  inclusion,  the  between-subject
variability  for  the  parameter  koutI was very small  and we removed it  from the final  model.  The
estimates of the effects of  these covariates are shown in Table 5.  For each continuous parameter-
covariate relationship, we show the values of the 10 and 90 th percentile of the distribution of this
covariate in our population (column 3), and the corresponding predicted values of the parameter for
that relationship, in order to illustrate the typical individual variability for this parameter. For example,
the release of iron during the rebound effect, characterised by parameter krel I, can be expected to vary
between 3.80 for women with a BMI of 19.3 and 1.32 for a  BMI of 26.6. The table also shows that
women without contraception eliminate iron about 22% faster than women taking contraception.
The method of contraception was significant in the final model, where we found that women
with contraception have a lower elimination of iron throughout the cycle, and consequently maintain
higher  iron  concentrations  than  women  without  contraception.  This  result  is  consistent  with  the
observed serum iron values, as we found iron concentrations at the last visit to be significantly higher
for  the  women  with  contraception  (p-value=0.008  according  to  a  Wilcoxon  test).  Higham  score
increases both the production and the elimination of hepcidin,  and the net  effect  results  in higher
concentrations  of  hepcidin  with  faster  return  to  equilibrium  for  high  scores.  Subjects  with  high
concentrations of ferritin at the end of the cycle visit tended to have slower elimination of hepcidin but
also  less  rebound  after  menses,  resulting  in  higher  concentrations  with  dampened  fluctuations
throughout the cycle. The height of the subjects had an important effect on the release of hepcidin at
the end of menses, with tall women showing a much more pronounced rebound than short women.
This  effect  was not  related to weight  or  body mass  index,  and remained highly significant  in  all
covariate models tested in the analysis. The final model with a proportional error model was subjected
to  a  run  assessment,  and  all  effects  remained significant  in  the  repeated  runs (additional  details,
including a figure showing the estimates of parameters and their standard errors across 10 runs starting
with different seeds and conditional estimates, are given in the Appendix).
To highlight the importance of including covariates, Table 4 compares the estimates of the
parameters and their standard errors in the models with and without covariates. The estimates of the
fixed parameters were similar  in both models but  the between-subject  variabilities were generally
smaller in the model with covariates. The model with covariates also performed better with respect to
the minimal value of the objective function and the value of both residual errors. The precisions of the
estimates in the final model were reasonable, with standard-errors less than 30%.
Model Evaluation
Individual fits of iron and hepcidin are shown in Figure 4 for the first  9 subjects in the
dataset.  The  two  responses  for  each  subject  are  shown  overlayed  on  the  same  figure,  iron  is
represented in red and hepcidin in blue, respectively with closed and open circles for measured values.
The model adequately described the evolution of both serum concentrations throughout the menstrual
cycle  for  most  subjects,  although  in  some  subjects  iron  fluctuated  daily  and  did  not  follow  a
recognisable evolution (subject 6 for iron and subject 2 for hepcidin, for example). The diagnostic
VPC in Figure 5 supports the good model adequacy for iron, since the observed median profile as well
as the 10th and 90th percentiles remain in their prediction intervals. The hepcidin serum concentrations
were more difficult to predict because of the high variability, and the individual fits and the diagnostic
VPC reflected these results,  which can be seen in  particular  in  the  higher  variability  for  the  90 th
percentile of data in Figure 5 (upper right). The evolution of hepcidin was poorly adjusted in some
subjects, especially when hepcidin did not return to a baseline level at the end of the cycle (subject 2 in
Figure 4 for example), and there was more diversity in the individual profiles. As a result, the VPC for
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hepcidin was less convincing than for iron, with a larger variability in particular in the magnitude of
the rebound. This variability reflects the fact that the rebound does not appear in all subjects, and also
that hepcidin does not always follow the evolution of iron. However, the model adequately described
the median and the 10th percentile for hepcidin, suggesting that we can capture the average evolution
of hepcidin. Finally, Figure 5 shows the plots of predicted versus observed values, for iron (top) and
hepcidin (bottom), using either population (left) or individual predictions (right). As can be expected
from the poor predictions for some observations, the plots show some outliers poorly predicted by the
model,  but  the  bulk  of  the  observations  are  distributed  around  the  line  of  identity.  The  NPDE
(normalised prediction distribution errors) versus time, in Figure 5 (bottom), support this conclusion.
As expected, the majority of the residuals of both iron and hepcidin fall within the interval [-1.96,
1.96], indicating no major model misspecification (27). Figure 6 presents the plots of the observed
versus  predicted  concentrations  for  iron  (top)  and  hepcidin  (bottom),  with  population  (left)  and
individual (right) predictions, with again more residual variability apparent for the second iron-status
variable.
Finally,  we  performed  two  assessments  of  the  model  robustness.  First,  we  ran  a  run
assessment to assess the stability when changing initial conditions and random number generator seed;
the estimates of the parameters remained stable across the different runs, revealing no major problem
of stability. Second, the model was adjusted again with the dataset excluding the three subjects with
abnormal  values  of  hepcidin.  The  fixed  estimates  of  the  model  parameters  (fixed  and  random
variability)  were  similar  to  those  obtained  in  the  full  dataset,  but  the  residual  error  of  hepcidin
decreased to 0.45; a couple of covariate effects were also slightly modified, but remained significant.
This suggests that the model considered the outlier data as noise, and confirmed the robustness of the
model estimates.
DISCUSSION
The objective  of  the  present  study was  to  model  the  evolution  of  serum iron  and serum
hepcidin concentrations throughout the menstrual cycle in healthy non menopausal women. Hepdicin
has attracted interest as a major player in the regulation of iron metabolism, and since the development
of an analytical method to measure its  serum concentration,  it  is being introduced in the array of
diagnostic tools for iron disorders (10). Little is known however about the within-subject variations to
be expected, in particular in women: significant diurnal variations of hepcidin have been reported (28),
and gender, as well as age, has been shown to impact the values of  hepcidin concentrations in normal
subjects (5,29-30). In addition, the evolution of martial settings including serum iron shows significant
variations during the menstrual cycle (4). To our knowledge ours is the first study to propose a joint
model of these two variables, and the first to propose a model explaining the fluctuations of hepcidin
during the menstrual cycle.
We used a population approach via non-linear mixed effect models to design the experiment
and model the data collected (18, 19). This enabled us to limit the number of samples in each woman,
as  an  important  loss  of  blood could  have  interfered  with  iron  regulation  and  therefore  modified
concentrations  of  iron-status  variables.  Non-linear  mixed  effect  models  are  also  able  to  handle
longitudinal data with different sampling times for each subject; this allowed us to adapt the sampling
schedule to cover the entire menstrual cycle over the population, while adjusting to weekdays for the
visits. An added benefit was the bolstered inclusion rate as the protocol was not deemed to be too
invasive.
The evolution of the two variables was jointly described using two linked turnover models
with increased elimination from blood loss  during menses.  Menses  were found to have a  similar
impact on both iron and hepcidin, as we could use the same parameter kloss to model the increased
elimination of the two variables. We found that iron levels modified the release of hepcidin, but we
could  not  identify  a  regulatory  effect  of  hepcidin  on  iron.  The  elimination  rate  of  hepcidin,
characterising the rate of turnover and the speed at which the system adjusts to perturbations, was
estimated in our study to be around 0.82 d-1 (half-life of 0.9 d). This reflects the equilibration time for
the iron regulatory system rather than the actual elimination half-life of hepcidin alone, which on its
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own is a very short-lived hormone, with a half-life estimated to a few minutes  in monkeys (19). The
fact that koutI and koutH are close supports this interpretation, as the elimination rate constant for iron
was estimated to be 0.42 d-1 (half-life of 1.7 d).
A second feature of the model was the increased release of both hepcidin and iron beginning
during menses, which was included in the model through the parameters krel I and krelH. to describe the
rebound observed mid-cycle. Rebound effects are characteristic of systems including regulation loops,
and can reflect  tolerance building up in the system as  it  adjusts to changing inputs  (24).  Various
tolerance models have been proposed, including push-pull models (25), effect compartment models
(26) and precursor models (32). We attempted to introduce mutual or one-way regulation of iron and
hepcidin to account for this phenomenon, but none of the different tolerance models tested was able to
describe  adequately  the  observed  rebound,  generally  falling  short  of  the  peak.  We also  explored
introducing the other iron-status variables into the model, as they are known to be involved in iron
circulation, but contrary to iron and hepcidin they showed little variation during the menstrual cycle,
except  for  transferrin  saturation  which  was  highly  correlated  with  iron  concentrations,  and  were
therefore unable to explain the variations during the first part of the cycle. Thus, the iron network was
simplified in this study where iron was only related to hepcidin. Interestingly, the increase in iron was
about nearly four times as large (41%) as the increase in hepcidin (11%), which can be related to the
fact  that  hepcidin  is  driven  mainly  by  iron  in  our  model,  while  iron  is  also  influenced by  deep
regulation mechanisms. The impact of iron on hepcidin was relatively small (=0.03) but significant,
as  models  without  the  link  function  were  found to  perform worse.  We also  tested  removing the
rebound for hepcidin so that the hepcidin profile was entirely driven by changes in iron concentration
but again the statistical criterion was slightly worse, showing that both intrinsic hepcidin rebound and
iron changes influence the evolution of hepcidin.
There was a considerable between subject variability in baseline concentrations for both iron
and hepcidin, reflected in large interindividual variability in key parameters in the model, notably the
elimination rate of hepcidin. Variability in iron-status variable loss during menses, or the extent of the
rebound effect,  also impact the within subject variability during the menstrual cycle on top of the
fluctuations  introduced  by  blood  loss  during  menses  and  the  subsequent  system regulation.  It  is
interesting to note that the study was performed in a relatively homogenous population of healthy
women, where we excluded subjects with low iron concentrations or haemoglobin at baseline. For
diagnosis  purposes  this  suggests  that  non-menopausal  women  are  likely  to  exhibit  significant
variations within their cycle on top of the within-subject variability, even in the absence of iron-related
disorders. Blood loss during menses is the main cause of iron deficiency in young women. It varies
between 20 and 80 ml during a period, representing a loss of 10 to 40 mg of iron for women with
regular menstrual cycles (16, 33). This is significant compared to the unregulated 1 mg eliminated
daily through skin,  intestinal  and  urinary cell  desquamation,  the  only  other  physiological  way to
eliminate  iron  (2).  Additional  sources  of  variability  may include  dietary  factors,  which  were  not
monitored or controlled in this study.
The joint model proved very satisfactory to describe the evolution of iron, with a residual
variability  of  30%,  while  the  residual  variability  remained  larger  for  hepcidin  (47%)  even  after
covariate  inclusion,  indicating  more  unexplained  fluctuations  for  this  variable.  This  reflects  the
observed data, as the evolution of iron was more consistent across the women than the evolution of
hepcidin.  Indeed,  in  about  two-thirds  of  the  subjects,  the  rebound of  hepcidin was small  or  non-
existent,  or  the  evolution  of  hepcidin  was  quite  different  from  the  evolution  of  iron.  Graphical
diagnostics illustrated this higher variability. We experimented with various other models for hepcidin,
including a mixture of subjects with or without rebound, as well as a cyclic menstrual variation in the
elimination rate constant of hepcidin during the cycle. Although this last model was promising, with a
reduced residual variability, it had the disadvantage of predicting large fluctuations in the second part
of the cycle, where the data to evaluate it was limited, so it was not kept in the final analysis. A total of
six iron-status variables were measured during the study, but only iron and hepcidin are included in the
model because the others did not show significant variations during the menstrual cycle. The exception
was  transferrin  saturation  which  was  almost  completely  correlated  with  iron  and  did  not  bring
additional information for the modelling. However, the typical (baseline) value of these variables was
taken into account as a covariate. Our results suggest that in this group of healthy women, menses are
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the main determinant of iron changes during a monthly cycle, and iron and hepcidin are the most
reactive iron-status variables.
The experimental design for the HEPMEN study was optimised based on three assumptions:
(i) a simplified turnover model of iron assuming only release and elimination of iron into the blood
stream;  (ii)  a  similar  evolution  of  hepcidin  with  parameters  estimated  in  monkeys  and  (iii)  an
additional elimination of both variables through blood loss during menses. As a result the optimised
protocol included more sampling times during the first part of the cycle where more variation was
expected. The data collected in the HEPMEN study however showed a significant rebound of iron
concentrations after the end of menses in most women, as well as of hepcidin in a large proportion of
women. In addition, some women exhibited different patterns for hepcidin evolution which could not
be adequately described by the model. It would therefore be interesting to collect additional data in the
second part of the menstrual cycle to further refine the model and evaluate the plausibility of cyclic
changes that could be associated with hormone status. 
In  the  present  study,  we  also  investigated  the  impact  of  a  number  of  covariates,  both
demographic and biological, on the variability of iron and hepcidin. Most covariate effects we found
had an impact on the steady-state levels of iron and hepcidin. At the end of the cycle, the model
predicts that hepcidin and iron both stabilise to a value representing the steady-state of the system in
the absence of the perturbation induced by menses or abnormal bleeding. The average baseline value
of iron was estimated to be 18 µmol.L-1, or equivalently 1 mg/L, and the average baseline value of
hepcidin was estimated to be 3.0 nmol.L-1. Those values are similar to baseline of previous studies
with similar population where iron baseline was estimated to 16.6 µmol.L -1 (4) and hepcidin baseline
was estimated between 2.6 and 4.8 nmol.L-1 depending on age (5). These baseline levels were found to
be affected by contraception method for iron and by serum ferritin for hepcidin. 
We found that women without contraception had a higher elimination of iron, which led to
steady-state concentrations of iron lower by about 20% compared to women using contraception. It
has been shown that contraception regulates the abundance of menses (34) and therefore limits iron
loss (35), which can explain this finding. Iron concentrations at steady-state were also affected by
body size, as we found that iron absorption decreased when the body mass index increased. This result
was observed in several studies revealing that iron concentration was lower for people with a high
body mass index (36-37). A study performed on women aged between 18 to 25 years with a measured
BMI ≥ 27.5 kg/m² revealed the presence of inflammation with increasing body mass index. However,
inflammation is a factor increasing hepcidin production and consequently decreasing iron absorption.
Finally, our model confirmed previous findings that haemoglobin concentrations have an impact on
iron  concentrations  (38).  We  found  that  iron  concentrations  were  lower  when  haemoglobin
concentrations were low. The production of haemoglobin is dependent on serum iron which binds to
transferrin  and  moved  to  the  bone  marrow  where  it  is  used  to  produce  erythrocytes  (2).  High
haemoglobin concentration decrease this stimulation, leaving more circulating iron in blood, which is
reflected in our model by an increased rebound of iron after menses. Similarly, several covariates were
also found to affect  levels of  hepcidin.  Higham’s score had an effect  both on the production and
elimination  of  hepcidin.  The  net  result  is  that  hepcidin  concentrations  are  lower  in  women
experiencing high blood loss during menses. High blood loss would also result  in more iron loss,
which would lead to higher hepcidin release to compensate. Finally, our model confirmed previous
observations of a significant correlation between hepcidin and ferritin (39-40). In healthy women, high
concentrations of ferritin correlate with high concentrations of iron, which would trigger an increase of
hepcidin to regulate iron release from storage. 
An unexpected finding was that height had a strong effect on the release of hepcidin at the end
of  menses,  with  tall  women  showing  a  more  pronounced  rebound  after  menses.  This  was  not
attributable to a particular subgroup of subjects, as the effect was quite strong and remained present in
all  models tested.  As weight  or  BMI are more often used as determinant  of  body size in PK/PD
analyses, we also considered these covariates in the analysis, but they did not have the same impact as
height.
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CONCLUSION
In  summary,  a  joint  turnover  model  with  time-varying  production  and  elimination  rate
constants was developed to describe serum iron and serum hepcidin concentrations throughout the
menstrual cycle. The elimination rate constant increased during menses, reflecting the loss of blood,
and the secretion rate constant was assumed to increase during the first part of the cycle, describing the
observed rebound in both molecules at  the end of menses.  An increased excretion of hepcidin in
response to increased concentration of iron, reflecting iron regulation was also modelled. This model
allowed a better understanding of the evolution of hepcidin throughout the cycle and its relationship
with iron changes. It was able to describe the significant variations of both variables throughout the
cycle, and highlighted a large daily variability reflected by the high residual of hepcidin. The model
will be applied to analyse the variations of iron and hepcidin throughout the cycle and determine the
optimal time to measure the concentrations of those molecules (41-43).
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TABLES
Table 1. Characteristics of covariates at the last visit (end of menstrual cycle)
Demographic variables Biological covariates (at the last visit)
Covariate Mean (SD) Covariate Mean (SD)
Age 27.6 (6.3) Serum transferrin 2.94 (0.5)
Height (cm) 165.4 (6.1) Serum ferritin 53.14 (44.3)
Weight (kg) 61.8 (9.2) Haemoglobin 13.48 (0.7)
Body mass index (kg/m²) 22.6 (3.0) Transferrin saturation 23.81 (8.3)
Waist circumference (cm) 77.2 (9.6)
Higham’s score 96.6 (60.5)
SD, standard deviation
Table  2: Models  tested  in  the  joint  analysis  of  iron  and  hepcidin.  The  log-likelihood  (LL)  was
computed by Importance Sampling for all models tested. A combined error model was used except
when indicated otherwise. 
Nb Description BIC (IS)
1 Separate models for iron and hepcidin 5751.3
2 Model with ksynI linear function of hepcidin concentration 5751.0
3 Model with ksynH linear function of iron concentration 5749.4
4 Model with both variables acting on each other 5768.4
5 ksynH linear function of iron concentration, same kloss 5736.5
6 ksynH linear function of iron concentration, same drel 5728.9
7 ksynH linear function of iron concentration, same drel, no IIV 5728.7
8 Mixture model on krelI 5735.2
9 Mixture model on krelH 5735.3
10 ksynH linear function of iron concentration, no rebound for hepcidin 5731.8
11 Final model, proportional error model 5712.0
12 Final model, aIron fixed to 0.001 5720.0
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Table 3: Covariate models tested in the joint analysis of iron and hepcidin. Full base (N=90)
Nb Description LL (IS) BIC (IS)
1 Base model, no covariates 5634.17 5728.7
2 Parameter ksynH – full model (all covariates) 5599.25
3 Parameter ksynH – removing covariates with p>0.2 5597.77
4 Parameter ksynH – reduced model after stepwise pruning 5601.50 5718.49
5 Parameter koutH – full model (all covariates) 5605.83
6 Parameter koutH – removing covariates with p>0.2 5605.46
7 Parameter koutH – reduced model after stepwise pruning 5602.22 5714.72
8 Parameter ksynI – full model (all covariates) 5591.01
9 Parameter ksynI – removing covariates with p>0.2 5584.00
10 Parameter ksynI – reduced model after stepwise pruning 5588.82 5701.31
11 Parameter koutI – full model (all covariates) 5589.64
12 Parameter koutI – removing covariates with p>0.2 5582.85
13 Parameter koutI – reduced model after stepwise pruning 5582.85 5704.34
14 Parameter kloss – full model (all covariates) 5613.80
15 Parameter kloss – removing covariates with p>0.2 5620.61
16 Parameter kloss – reduced model after stepwise pruning 5620.61 5724.11
17 Parameter krelI – full model (all covariates) 5625.23
18 Parameter krelI – removing covariates with p>0.2 5616.80
19 Parameter krelI – reduced model after stepwise pruning 5619.53 5727.52
20 Parameter krelH – full model (all covariates) 5627.29
21 Parameter krelH – removing covariates with p>0.2 5625.87
22 Parameter krelH – reduced model after stepwise pruning 5628.21 5731.71
23 Parameter drel – full model (all covariates) 5634.81
24 Parameter drel – removing covariates with p>0.2 -
25 Parameter drel – reduced model after stepwise pruning - -
26 Parameter  – full model (all covariates) 5627.67
27 Parameter  – removing covariates with p>0.2 5633.77
28 Parameter  – reduced model after stepwise pruning 5626.46 5725.46
29 Joint model combining separate parameter models 5636.71 5731.21
30 Final model after stepwise pruning 5565.16 5691.16
31 Final model, aIron fixed to 0.001 5563.23 5684.73
32 Final model, proportional error model 5558.49 5679.98
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Table 4. Estimates of the parameters and their variability for both models with and without covariates
Model without covariate Model with covariates
Parameter Estimate (RSE) Variability (RSE) Estimate (RSE) Variability (RSE)
ksynI (µmol.d. L-1) 5.48 (10) 13 (64) 7.57 (8) 15 (15)
koutI (d-1) 0.33 (10) 14 (51) 0.42 (8) 0 (-)
kloss (d-1) 0.08 (27) 129 (20) 0.14 (19) 95 (19)
krelI (µmol.d.L-1) 2.23 (14) 70 (19) 2.55 (13) 55 (22)
drel (d) 5.44 (10) 0 (-) 5.74 (5) 0 (-)
ksynH (nmol.d.L-1) 1.86 (9) 50 (12) 2.48 (5) 24 (19)
koutH (d-1) 0.58 (9) 51 (12) 0.82 (7) 57 (9)
krelH (nmol.d.L-1) 0.21 (25) 156 (13) 0.28 (21) 103 (17)
α (-) 0.03 (35) 64 (67) 0.03 (31) 87 (38)
bIron (-) 0.29 (4) 0.29 (4)
aHep (nmol.L-1 ) 0.14 (48) 0.17 (50)
bHep (-) 0.48 (7) 0.47 (8)
-2LL (IS) 5631.0 5558.5
BIC (IS) 5721.0 5680.0
RSE,  relative  standard  error,  in  %;  d,  day;  BIC,  Bayesian  Information  Criterion;  IS,  importance
sampling; -2LL, objective function. The variability is in %.
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Table 5. Estimates of the covariates effects (β) on the parameters of the final model
Parameter Covariate Estimate of β (RSE) Covariate distribution(10-90th percentile)
Estimate 
(10-90th percentile)
koutI
No 
contraception  0.20 (23) 0 - 1 0.38-0.46
krelI BMI -3.31 (31) 19.3 – 26.6 3.80-1.32
Haemoglobin*  6.93 (31) 12.5 – 14.6 1.54-4.53
ksynH Higham  0.66 (11) 38.2 – 160.2 0.61-1.58
koutH Higham  0.83 (14) 38.2 – 160.2 0.18-0.59
Ferritin* -0.60 (16) 18.6 – 97.4 0.50-0.18
krelH Height  32.70 (16) 158.0 – 173.0 0.03-0.58
Ferritin* -1.95 (18) 18.6 – 97.4 0.57-0.03
*baseline
RSE,  relative  standard  error,  in  %;  10-90;  CI:  confidence  interval  for   (computed  as  estimated+/-
1.96*SE); Assessment: mean (min/max) of 5 values estimated during the run assessment step values
of the 10th and the 90th percentile of the covariate.
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FIGURES
Figure 1. Simplified processes of  iron absorption and circulation in the mammalian body.
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Figure 2. Evolution of iron-status variables during the menstrual cycle in the Hepmen study, shown as
boxplots. The Y-axis for the hepcidin plot was set to 0-20, excluding 7 outlying observations from the
23
plot to better show the evolution during the cycle. The width of each box is proportional to the number
of observations collected on each day. 
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Figure 3. Model for iron and hepcidin in non-menopausal women (left), and values of the parameters
controlling the turnover of both molecules according to the time in menstrual cycle (right).
Figure 4. Individual  fits  for  the first  9 subjects in the dataset,  for iron (red, closed symbols)  and
hepcidin  (blue,  open  circles).  The  symbols  on  the  individual  fits  represent  individual  measured
concentrations, and the solid lines represent model predictions. 
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Figure 5. Diagnostic VPC (top) and graphs of the NPDE (bottom), as obtained with the Monolix
software for iron (left) and hepcidin (right). The solid lines represent the 10 th, 50th and 90th empirical
percentiles of the measured concentrations in the diagnostics VPC and of empirical percentiles of the
residuals in the NPDE graphs. The coloured areas represent the 90% prediction interval associated
with the 10th, 50th and 90th theoretical percentile in the first case and the confidence interval in the
second.
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Figure  6. Prediction  versus  observations  for  iron  (top)  and  hepcidin  (bottom),  with  population
predictions (left) and individual predictions (right).
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